Methods of treating cancer with placenta growth factor peptide linked to immunotherapeutic antibodies
US11574747B2 · kind B2 · utility
0Cited by
1References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 20, 2018 |
| Grant date | Feb 7, 2023 |
| Priority date | — |
| Expiry date | Aug 10, 2038 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG21F5/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The methods and compositions described herein address the need in the art by providing compositions and methods for a therapy with an antibody that is specifically targeted to and/or retained intra- or peri-tumorally, limiting systemic exposure and reducing side-effects. Accordingly, aspects of the disclosure relate to a composition comprising an immunotherapeutic antibody operatively linked to an extracellular matrix (ECM)-affinity peptide. An ECM-affinity peptide is one that has affinity for an extracellular matrix protein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.